Tenet Healthcare (THC) Expected to Announce Quarterly Earnings on Friday

Tenet Healthcare (NYSE:THC) is expected to be announcing its Q2 2026 results before the market opens on Friday, July 24th. Analysts expect the company to post earnings of $4.26 per share and revenue of $5.4316 billion for the quarter. Tenet Healthcare has set its FY 2026 guidance at 16.380-18.68 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, July 24, 2026 at 11:30 AM ET.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings results on Thursday, April 30th. The company reported $4.82 EPS for the quarter, topping the consensus estimate of $4.21 by $0.61. Tenet Healthcare had a return on equity of 25.55% and a net margin of 7.94%.The company had revenue of $5.37 billion for the quarter, compared to the consensus estimate of $5.39 billion. During the same period in the previous year, the business posted $4.36 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. On average, analysts expect Tenet Healthcare to post $18 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Tenet Healthcare Stock Up 3.6%

Shares of THC stock opened at $199.17 on Friday. The stock has a 50 day moving average of $184.26 and a 200-day moving average of $197.50. The firm has a market cap of $17.16 billion, a PE ratio of 10.36, a price-to-earnings-growth ratio of 1.59 and a beta of 1.27. The company has a quick ratio of 1.30, a current ratio of 1.36 and a debt-to-equity ratio of 1.96. Tenet Healthcare has a 12 month low of $146.60 and a 12 month high of $247.21.

Analyst Ratings Changes

THC has been the subject of several research analyst reports. Royal Bank Of Canada cut their target price on shares of Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating for the company in a research note on Friday, May 1st. Wall Street Zen downgraded shares of Tenet Healthcare from a “strong-buy” rating to a “buy” rating in a report on Monday, May 11th. Morgan Stanley set a $254.00 target price on shares of Tenet Healthcare in a research note on Friday, May 1st. Weiss Ratings downgraded Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, June 2nd. Finally, Stephens cut their price target on Tenet Healthcare from $275.00 to $260.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Eighteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.37.

Insider Buying and Selling

In other Tenet Healthcare news, Director Nadja West sold 3,000 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the completion of the transaction, the director directly owned 24,805 shares in the company, valued at $4,399,166.75. This represents a 10.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total value of $983,943.76. Following the transaction, the director directly owned 16,804 shares of the company’s stock, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.97% of the company’s stock.

Institutional Investors Weigh In On Tenet Healthcare

Hedge funds have recently made changes to their positions in the company. Triumph Capital Management bought a new position in Tenet Healthcare during the 3rd quarter valued at about $25,000. Canada Pension Plan Investment Board acquired a new stake in shares of Tenet Healthcare during the second quarter worth approximately $35,000. Meeder Asset Management Inc. raised its stake in shares of Tenet Healthcare by 146.2% in the fourth quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after acquiring an additional 114 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Tenet Healthcare by 50.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock worth $46,000 after acquiring an additional 89 shares in the last quarter. Finally, Wilkerson Advisory Group LLC bought a new stake in Tenet Healthcare during the 4th quarter worth approximately $62,000. Institutional investors and hedge funds own 95.44% of the company’s stock.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.